Gain Therapeutics, Inc. (NASDAQ:GANX) Short Interest Update

Gain Therapeutics, Inc. (NASDAQ:GANX) saw a significant increase in short interest in October. As of October 31st, there was short interest totalling 658,300 shares, an increase of 15.1% from the October 15th total of 572,000 shares. Based on an average daily volume of 404,400 shares, the days-to-cover ratio is presently 1.6 days. Currently, 2.7% of the company’s stock are sold short.

Institutional Trading of Gain Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Warberg Asset Management LLC purchased a new stake in shares of Gain Therapeutics during the second quarter worth approximately $66,000. Renaissance Technologies LLC increased its position in shares of Gain Therapeutics by 154.2% during the second quarter. Renaissance Technologies LLC now owns 118,700 shares of the company’s stock worth $152,000 after purchasing an additional 72,000 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Gain Therapeutics by 48.0% during the third quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock worth $484,000 after purchasing an additional 88,236 shares in the last quarter. Finally, Hohimer Wealth Management LLC acquired a new position in Gain Therapeutics during the second quarter worth $422,000. 11.97% of the stock is currently owned by hedge funds and other institutional investors.

Gain Therapeutics Trading Up 5.7 %

Shares of NASDAQ:GANX opened at $1.85 on Monday. Gain Therapeutics has a 12-month low of $0.89 and a 12-month high of $5.33. The company has a market capitalization of $47.10 million, a PE ratio of -1.68 and a beta of 0.33. The business has a 50 day moving average of $2.03 and a two-hundred day moving average of $1.76. The company has a current ratio of 2.84, a quick ratio of 2.84 and a debt-to-equity ratio of 0.03.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective on shares of Gain Therapeutics in a research report on Wednesday, October 9th. Oppenheimer reaffirmed an “outperform” rating and set a $8.00 price objective on shares of Gain Therapeutics in a research report on Wednesday, August 14th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $6.00 price objective on shares of Gain Therapeutics in a research report on Friday, August 9th.

About Gain Therapeutics

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.